A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease

Trial Profile

A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 02 Nov 2017 Planned primary completion date changed from 28 Dec 2022 to 23 Sep 2022.
    • 02 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 May 2017 Planned End Date changed from 5 Nov 2025 to 28 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top